Interleukin-6 blocking agents for treating COVID-19: a living systematic review-Reference-Cited by-同舟云学术

Interleukin-6 blocking agents for treating COVID-19: a living systematic review

Published:2023-06-01 Issue:6 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ghosn Lina¹²³,Assi Rouba¹²³,Evrenoglou Theodoros³,Buckley Brian S⁴,Henschke Nicholas⁴,Probyn Katrin⁴,Riveros Carolina²³,Davidson Mauricia³,Graña Carolina¹²³,Bonnet Hillary¹³,Jarde Alexander³,Ávila Camila⁵,Nejstgaard Camilla Hansen⁶⁷,Menon Sonia¹,Ferrand Gabriel¹,Kapp Philipp⁸,Breuer Claudia⁸⁹,Schmucker Christine⁸⁹,Sguassero Yanina⁴,Nguyen Thu Van¹,Devane Declan¹⁰¹¹¹²,Meerpohl Joerg J⁸⁹,Rada Gabriel⁵¹³,Hróbjartsson Asbjørn⁶⁷,Grasselli Giacomo¹⁴,Tovey David¹,Ravaud Philippe¹²³,Chaimani Anna¹²³,Boutron Isabelle¹²³

Affiliation:

1. Cochrane France; Paris France

2. Centre d’Epidémiologie Clinique, AP-HP, Hôpital Hôtel Dieu, F-75004; Paris France

3. Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France

4. Cochrane Response; Cochrane; London UK

5. Epistemonikos Foundation; Santiago Chile

6. Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark; Department of Clinical Research, University of Southern Denmark; Odense Denmark

7. Open Patient data Explorative Network (OPEN); Odense University Hospital; Odense Denmark

8. Institute for Evidence in Medicine (for Cochrane Germany Foundation); Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany

9. Cochrane Germany; Cochrane Germany Foundation; Freiburg Germany

10. Evidence Synthesis Ireland; Galway Ireland

11. Cochrane Ireland and HRB-Trials Methodology Research Network; Galway Ireland

12. University of Galway; Galway Ireland

13. UC Evidence Center, Cochrane Chile Associated Center; Pontificia Universidad Católica de Chile; Santiago Chile

14. Department of Anesthesia, Intensive Care and Emergency Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan; Milan Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference163 articles.

1. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS) clinicaltrials.gov/ct2/show/NCT04412772

2. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis;WHO REACT Working Group 2021;JAMA,2021

3. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial;Branch-Elliman;PLoS One,2022

4. Sarilumab for patients with moderate COVID-19 disease clinicaltrials.gov/ct2/show/NCT04359901

5. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study;Broman;Clinical Microbiology and Infection,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polypharmacy and the In Silico Prediction of Potential Body Proteins Targeted by These Drugs Among Hospitalized COVID-19 Patients With Cytokine Storm;Cureus;2023-11-15

2. Medical technologies assessment in COVID-19;HIV Infection and Immunosuppressive Disorders;2023-10-21

3. For adults with COVID-19, what are the effects of the interleukin-6 blocking agents tocilizumab and sarilumab?;Cochrane Clinical Answers;2023-08-08